Anti-cyclic citrullinated peptide (anti-CCP) antibody in juvenile idiopathic arthritis (JIA): Correlations with disease activity and severity of joint damage (a multicenter trial)

Joint Bone Spine

Volumn 80, Issue 1, 2013, Pages 38-43

  Omar, Aziza ^a   Abo Elyoun, Ihab ^b   Hussein, Hanan ^b   Nabih, Mohammad ^b,c   Atwa, Hoda ^a   Gad, Suzan ^a   Emad, Yasser ^b,c  

^a Suez Canal University Faculty of Medicine   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

^c Dr Erfan and Bagedo General Hospital   (Saudi Arabia)

Author keywords

Anti cyclic citrullinated peptide antibodies (Anti CCP); Juvenile Arthritis Disease Activity Score (JADAS); Juvenile idiopathic arthritis (JIA); Sharp Van der Heijde Radiological Score

Indexed keywords

ANTINUCLEAR ANTIBODY; C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; IMMUNOGLOBULIN M; RHEUMATOID FACTOR;

ADOLESCENT; ARTICLE; BLOOD CELL COUNT; CHILD; CLINICAL EXAMINATION; DISEASE ACTIVITY; DISEASE SEVERITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; JUVENILE ARTHRITIS DISEASE ACTIVITY SCORE; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; MALE; POLYARTHRITIS; PRESCHOOL CHILD; SCHOOL CHILD; SCORING SYSTEM; SHARP VAN DER HEIJDE SCORE;

ARTHRITIS, JUVENILE RHEUMATOID; AUTOANTIBODIES; CHILD; FEMALE; HUMANS; MALE; PEPTIDES, CYCLIC; SEVERITY OF ILLNESS INDEX;

EID: 84872839883     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2012.03.008     Document Type: Article

References (34)

1. Brabnikova Maresova K. Secondary osteoporosis in patients with juvenile idiopathic arthritis. J Osteoporos 2011, 20:569417.
2. Ringold S., Burke A., Glass R.M. JAMA patient page. Juvenile idiopathic arthritis. JAMA 2005, 294:1722.
3. Syed R.H., Gilliam B.E., Moore T.L. Rheumatoid factors and anticyclic citrullinated peptide antibodies in pediatric rheumatology. Curr Rheumatol Rep 2008, 10:156-163.
4. Woo P., Wedderburn L.R. Juvenile chronic arthritis. Lancet 1998, 351:969-973.
5. Symmons D.P.M., Jones M., Osborne J., et al. Pediatric rheumatology in the United Kingdom: data from the British Pediatric Rheumatology Group National Diagnostic Register. J Rheumatol 1996, 23:1975-1980.
6. Gedalia A., Molina I.F., Garcia C.O., et al. Anticardiolipin antibodies in childhood rheumatic disorders. Lupus 1998, 7:551-553.
7. Serra C.R.B., Rodrigues S.H., Silva N.P., et al. Clinical significance of anticardiolipin antibodies in juvenile idiopathic arthritis. Clin Exp Rheumatol 1999, 17:375-380.
8. Avcin T., Ambrozic A., Bozic B., et al. Estimation of anticardiolipin antibodies, anti-b2 glycoprotein I antibodies and lupus anticoagulant in a prospective longitudinal study of children with juvenile idiopathic arthritis. Clin Exp Rheumatol 2002, 20:101-108.
9. Nesher G., Moore T.L., Grisanti M.W., et al. Antiperinuclear factor in juvenile rheumatoid arthritis. Ann Rheum Dis 1992, 51:350-352.
10. Gabay C., Prieur A.M., Meyer O. Occurrence of antiperinuclear, antikeratin, and anti-RA33 antibodies in juvenile chronic arthritis. Ann Rheum Dis 1993, 52:785-789.
11. el-Gamal Y., Hossny E., Mabrouk R., et al. Antiperinuclear factor in the diagnosis of juvenile rheumatoid arthritis. Pediatr Allergy Immunol 1995, 6:165-169.
12. Serra C.R.B., Rodrigues S.H., Sztajnbok F.R., et al. Antiperinuclear factor and antibodies to the stratum corneum of rat esophagus in juvenile idiopathic arthritis. J Pediatr 1999, 134:507-509.
13. Hromadníková I., Vavrincova P., Stechova K., et al. Anti-keratin antibodies in patients with juvenile idiopathic arthritis. Clin Exp Rheumatol 2001, 19:470-473.
14. Avcin T., Cimaz R., Falcini F., et al. Prevalence and clinical significance of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Ann Rheum Dis 2002, 61:608-611.
15. Gheita TA, Bassyouni IH, Emad Y, et al. Elevated BAFF (BLyS) and APRIL in juvenile idiopathic arthritis patients: relation to clinical manifestations and disease activity. Joint Bone Spine 2011; . doi:10.1016/j.jbspin.2011.05.019.
16. Petty R.E., Southwood T.R., Manners P., et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004, 31:390-392.
17. Consolaro A., Ruperto N., Bazso A., et al. Paediatric Rheumatology International Trials Organisation. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum 2009, 61:658-666.
18. Sharp J.T., Lidsky M.D., Collins L.C., et al. Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities. Arthritis Rheum 1971, 14:706-720.
19. Quartier P. Current treatments for juvenile idiopathic arthritis. Joint Bone Spine 2010, 77:511-516. [Epub 2010 Oct 18].
20. Amine B., Ibn Yacoub Y., Rostom S., et al. Prevalence of overweight among Moroccan children and adolescents with juvenile idiopathic arthritis. Joint Bone Spine 2011, 78:584-586. [Epub 2011 Mar 26].
21. Nienhuis R.L., Mandema E. A new serum factor in patients with rheumatoid arthritis; the antiperinuclear factor. Ann Rheum Dis 1964, 23:302-305.
22. Young B.J., Mallya R.K., Leslie R.D., et al. Anti-keratin antibodies in rheumatoid arthritis. Br Med J 1979, 2:97-99.
23. Simon M., Girbal E., Sebbag M., et al. The cytokeratin filament-aggregating protein filaggrin is the target of the so-called antikeratin antibodies, autoantibodies specific for rheumatoid arthritis. J Clin Invest 1993, 92:1387-1393.
24. Sebbag M., Simon M., Vincent C., et al. The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J Clin Invest 1995, 95:2672-2679.
25. Schellekens G.A., Visser H., de Jong B.A., et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000, 43:155-163.
26. van Gaalen F.A., Visser H., Huizinga T.W. A comparison of the diagnostic accuracy and prognostic value of the first and second anti-cyclic citrullinated peptides (CCP1 and CCP2) autoantibody tests for rheumatoid arthritis. Ann Rheum Dis 2005, 64:1510-1512.
27. Aletaha D., Neogi T., Silman A.J., et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010, 62:2569-2581.
28. Gupta R., Thabah M.M., Vaidya B., et al. Anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Indian J Pediatr 2010, 77:41-44.
29. Habib H.M., Mosaad Y.M., Youssef H.M. Anti-cyclic citrullinated peptide antibodies in patients with juvenile idiopathic arthritis. Immunol Invest 2008, 37:849-857.
30. Kwok J.S., Hui K.H., Lee T.L., et al. Anti-cyclic citrullinated peptide: diagnostic and prognostic values in juvenile idiopathic arthritis and rheumatoid arthritis in a Chinese population. Scand J Rheumatol 2005, 34:359-366.
31. Kasapçopur O., Altun S., Aslan M., et al. Diagnostic accuracy of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Ann Rheum Dis 2004, 63:1687-1689.
32. van Rossum M., van Soesbergen R., de Kort S., et al. Anti-cyclic citrullinated peptide (anti-CCP) antibodies in children with juvenile idiopathic arthritis. J Rheumatol 2003, 30:825-828.
33. Brunner J., Sitzmann F.C. The diagnostic value of anti-cyclic citrullinated peptide (CCP) antibodies in children with Juvenile Idiopathic Arthritis. Clin Exp Rheumatol 2006, 24:449-451.
34. Skare T.S., Nisihara R.M., Silva R.M., et al. Anti-cyclic citrullinated Peptide antibodies in adult patients with juvenile idiopathic arthritis. J Clin Rheumatol 2011, 17:421-423.